Platform comparison—amplicon-specific error rates.

<p>HTS platform-specific substitution (A) and Indel (B) error rates for amplicon libraries sequenced by 454 (black), Illumina (white), and IonTorrent (light grey) platform are displayed for single amplicons covering corresponding exons of the CREBBP gene.</p

Platform comparison—error rates.

<p>Platform comparison—error rates.</p

Universal two-step PCR approach.

<p>First-round PCR is performed by using gene-specific primers tailed with a universal linker sequence (light and dark green). The universal tailed amplicons can be used for second-round PCR, where deep sequencing platform-specific adapters can be introduced for either PGM (dark red), Illumina (blue), or 454 (orange). *To prepare PGM amplicon libraries containing trP1 and A adapter sequences on both ends of the library the second-round PCR has to be separated in two reactions with different primer combinations, respectively. All platform-specific amplicon libraries can be prepared with unique barcodes to sequence multiple samples.</p

Platform comparison—base quality & read length quality assessment.

<p>Per base quality scores and read length of all three platforms are shown for 454 (A, D), Illumina (B, E), and IonTorrent (C, F) using FASTQC algorithm.</p

Platform comparison—run details.

<p>Platform comparison—run details.</p

Platform comparison—read distribution.

<p>Total number of reads (coverage) for each single barcoded amplicon library generated by 454 (A), Illumina (B), and IonTorrent (C) platform are shown in both forward (light grey) and reverse (dark grey) read orientation.</p

Platform comparison—Base-specific error rates.

<p>Platform comparison—Base-specific error rates.</p

Microbiota composition of patients A, B, C, and D.

<p>(A) total microbiota (16S rRNA gene) (B) active microbiota (16S rRNA transcripts). The mode of action for each AB used is indicated.</p

Functional profiles.

<p>Main roles and sub-roles that change significantly during treatment and their associated p-values (p-value < 0.05). The upward arrow indicates those categories that were more abundant during treatment and the downward arrow those that were less abundant. NS, not significant.</p>*<p>Biosynthesis of cofactors, prosthetic groups, and carriers.</p>**<p>Biosynthesis and degradation of surface polysaccharides and lipopolysaccharides.</p

Main features of the follow-up study.

<p>AB, antibiotic; D, during the treatment.</p